Clinical trials: Epirubicin
Stomach Neoplasms
Docetaxel and Epirubicin in Advanced Gastric Cancer
1.Study rationale:There is no standard regimen for the advanced and/or metastatic gastric cancer patients who relapsed after adjuvant chemotherapy or failed to first systemic chemotherapy.
- Trial name
- NCT00375999
- Testing
- Docetaxel and epirubicin
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Yonsei University
HR Positive/HER2 Low Breast Cancer
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
This study is a prospective, multi-cohort, multicenter, open-label exploratory clinical trial. The primary study objective is to evaluate the pathologic complete response (PCR) of treatment of HR+/HER2-low breast cancer with…
- Trial name
- NCT07383818
- Testing
- Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab, Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 111 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Oesophago-gastric Cancer
REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer
To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients…
- Trial name
- REAL3 (NCT00824785)
- Testing
- epirubicin, oxaliplatin, capecitabine (EOX), EOX + panitumumab
- Where
- 7 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Neoplasms
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment…
- Trial name
- NCT00242203
- Testing
- Zometa, Epirubicin, Docetaxel
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Sarcoma, Soft Tissue
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR)…
- Trial name
- ALTER-S005 (NCT03815474)
- Testing
- anlotinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum
Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Patients with histological proven gastric cancer (including cancer of the esophagogastric junction (AEG)) and synchronous peritoneal carcinomatosis, who fulfill the inclusion and exclusion criteria, can be recruited in this…
- Conditions
- Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum, Secondary Malignant Neoplasm of Other and Unspecified Sites
- Trial name
- GASTRIPEC (NCT02158988)
- Testing
- HIPEC
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Charite University, Berlin, Germany
HER2 Negative Gastric Cancer
Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma
The purpose of the study is to compare efficacy and safety of palliative chemotherapy EOX and mDCF regimens in the first-line treatment of patients with advanced HER2-negative gastric and gastroesophageal junction (GEJ)…
- Trial name
- NCT02445209
- Testing
- EOX, mDCF
- Volunteers
- 56 people
- Sponsor
- Jagiellonian University
Breast Cancer
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
The goal of this clinical research study is to learn how effective the combination of chemotherapy including both panitumumab, Abraxane (nab-paclitaxel), and carboplatin (PNC) and fluorouracil, epirubicin, and cyclophosphamide…
- Trial name
- NCT01036087
- Testing
- Panitumumab, Nab-paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
The overarching purpose of this study is to determine if the mainstay chemotherapeutic regimens represented by several genotoxic agents including but not limited to Cyclophosphamide, Doxorubicin, Epirubicin, Fluorouracil and…
- Trial name
- COC-IDCB (NCT02897700)
- Testing
- Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
pCR Rate, BCT Rate
NeoMET Study in Neoadjuvant Treatment of Breast Cancer
To evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in neoadjuvant treatment of breast cancer patients.
- Conditions
- pCR Rate, BCT Rate, Safety
- Trial name
- NeoMET (NCT01929811)
- Testing
- Metformin, Docetaxel, Epirubicin
- Where
- 2 sites in China
- Volunteers
- 92 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
HER2/Neu Positive, Stage IA Breast Cancer
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
This randomized phase III trial is studying giving fluorouracil together with epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab to see how well it works compared with giving paclitaxel together with…
- Conditions
- HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00513292
- Testing
- Cyclophosphamide, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 115 sites in United States, Puerto Rico
- Volunteers
- 280 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
This is a Phase 1B/2, non-randomized, dose-escalation, multicenter, open-label study designed to evaluate the safety and tolerability of robatumumab (SCH 717454, MK-7454) in combination with standard treatment in participants…
- Trial name
- NCT00954512
- Testing
- Carboplatin, Epirubicin, Trastuzumab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Initially Unresectable Hepatocellular Carcinoma
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular…
- Trial name
- NCT07480382
- Testing
- Liver Venous Deprivation (LVD), Conventional Transarterial Chemoembolization(C-TACE), Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hong Wu
Signet Ring Cell Gastric Adenocarcinoma
Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled trial comparing primary surgery versus primary chemotherapy followed by surgery in patients with a resectable signet ring cell gastric…
- Trial name
- ADCI002 (NCT01717924)
- Testing
- peri-operative chemotherapy, Surgery first
- Where
- France
- Volunteers
- 314 people
- Sponsor
- University Hospital, Lille
Breast Neoplasms
Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
Prospective, monoinstitutional, phase II study. Patients with HER 2 positive locally advanced breast cancer will be treated with 3 initial cycles (12 weeks) of trastuzumab plus paclitaxel and then if responding further 12 weeks…
- Trial name
- NCT02307227
- Testing
- Trastuzumab, Paclitaxel, Epirubicin
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Cancer, Stage I Breast Cancer
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00146588
- Testing
- Cyclophosphamide, Epirubicin, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Craig A. Bunnell, MD, MPH
Metastatic Breast Cancer
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Paclitaxel plus Epirubicin in metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline.
- Trial name
- NCT02207361
- Testing
- Paclitaxel, Carboplatin, Paclitaxel, Epirubicin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stage IIB Breast Cancer, Stage IIIA Breast Cancer
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
The primary purpose of this study is to determine whether locally advanced breast cancer responds (by shrinking, by not progressing or by being destroyed) to combined chemotherapy (gemcitabine, epirubicin and paclitaxel) given…
- Conditions
- Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00378313
- Testing
- gemcitabine, epirubicin, paclitaxel
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- NSABP Foundation Inc
Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast…
- Trial name
- NCT06358573
- Testing
- INT230-6, neoadjuvant immuno-chemotherapy
- Where
- 10 sites in France, Switzerland
- Volunteers
- 61 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
The randomized LITE study will compare liposomal doxorubin versus standard epirubicin in the treatment of female breast cancer. In order to detect as early as possible post-chemotherapy cardiotoxicity, tissue Doppler imaging…
- Trial name
- LITE (NCT00531973)
- Testing
- liposomal doxorubicin, epirubicin
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Catholic University, Italy